Gonadorelin vs HCG
A side-by-side research comparison of Gonadorelin and HCG across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Gonadorelin | HCG |
|---|---|---|
| Full name | Gonadorelin (GnRH Analog) | Human Chorionic Gonadotropin |
| Category | Hormone Replacement | Hormone Replacement |
| Status | FDA Approved | FDA Approved |
| Mechanism | Binds GnRH receptors on pituitary gonadotrophs to stimulate LH and FSH release, maintaining testicular/ovarian function and natural sex hormone production. | Binds LH/CG receptors on Leydig cells, stimulating intratesticular testosterone synthesis and maintaining spermatogenesis via local paracrine signaling independent of pituitary FSH/LH. |
| Molecular weight | 1182.39 Da | ~36,700 Da |
| Half-life | ~10-40 minutes | ~33 hours |
| Bioavailability | ~90% subcutaneous | ~100% (subcutaneous/intramuscular) |
| Typical dose | 100-500 mcg | 500-1000 IU |
| Frequency | 2-3x per week or pulsatile | 2-3x per week |
| Route | Subcutaneous injection | Subcutaneous injection |
Gonadorelin reported benefits
- Maintains natural hormone production
- Fertility preservation
- Testicular function support
- LH/FSH normalization
HCG reported benefits
- Preserved testicular size
- Maintained fertility on TRT
- Intratesticular testosterone
- Improved mood (neurosteroid support)
- Pregnenolone/DHEA maintenance
Related comparisons
Research and educational reference only. Not medical advice.